Bupropion

Prospective randomized double-blinded crossover study examining bioequivalence of generic and brand bupropion HCl 300 mg XL in adults with major depressive disorder in remission for at least 4 months.

Long-term relapse-prevention study demonstrated that patients maintained on bupropion SR (150 mg twice daily) had significantly lower relapse rates compared to placebo, with median time to relapse exceeding 44 weeks versus 24 weeks for placebo group.

Meta-analysis of 27 trials found bupropion efficacious in reducing depression scores in 24 trials, demonstrating comparable effectiveness to other antidepressant classes including SSRIs and SNRIs, with statistical superiority to placebo on depression rating scales.

Study comparing 40 depressed patients receiving bupropion to matched healthy controls, measuring changes in brain hemodynamic response, mood, anhedonia, cognitive accuracy and reaction time over 6 weeks.

Meta-analysis of 27 trials found bupropion efficacious in reducing depression scores in 24 trials, demonstrating comparable effectiveness to other antidepressant classes including SSRIs and SNRIs, with statistical superiority to placebo on depression rating scales.

Study examining efficacy of bupropion extended-release (up to 450 mg) combined with naltrexone versus placebo for weight loss in individuals with elevated BMI, with measurements of weight, BMI, waist circumference, and metabolic markers.

Long-term study found that 67% of participants taking bupropion who completed the first eight weeks lost more than 5% of their baseline body weight.